Cancer Immunology, Immunotherapy

, Volume 35, Issue 4, pp 271–276 | Cite as

Cellular immunosuppression in children with acute lymphoblastic leukemia: Effect of consolidation chemotherapy

  • Yoshihiro Komada
  • Shao-Li Zhang
  • Yan-Wen Zhou
  • Motoi Hanada
  • Takeo Shibata
  • Eiichi Azuma
  • Minoru Sakurai
Original articles

Summary

The present study was designed to evaluate the chemotherapy-induced cellular immunosuppression in 20 children with acute lymphoblastic leukemia (ALL) in remission and receiving maintenance chemotherapy. Peripheral blood was serially obtained from leukemic children during vincristine/cyclophosphamide/6-mercaptopurine/prednisone combined consolidation chemotherapy. The mean absolute number of peripheral blood lymphocytes as well as the mean absolute numbers of lymphocyte subsets (T cells, T cell subsets, B cells, and natural killer cells) from leukemic children before consolidation chemotherapy were all significantly lower than in control subjects; however, the percentages of lymphocyte subsets were similar in both groups. After consolidation chemotherapy, the percentages of CD4+ T lymphocytes and natural killer (NK) cells were significantly decreased and the percentages of monocytes and CD8+ T lymphocytes were significantly increased. Phytohemagglutinin- and 12-O-tetradecanoylphorbol-13-acetate-induced production of interleukin-2 (IL-2) and NK-cell-mediated cytotoxic activity by peripheral blood mononuclear cells (PBMC) were also substantially decreased in the post-therapy groups. NK activity correlated with the percentage of NK cells in PBMC. In contrast, OK432-induced production of tumor necrosis factor α (TNFα) and killer activity against NK-resistant target cells were significantly increased after therapy as compared with the pre-therapy and control groups. TNFα production correlated with the percentage of monocytes in PBMC. These results demonstrate that substantial quantitative and qualitative chemotherapy-induced abnormalities of the cellular immune system are present in the majority of patients treated with ALL. It is also suggested that the increased TNFα production by monocytes and the appearance of potent killing activity against NK-resistant targets might compensate for the defects of IL-2 production and NK activity during intensive consolidation chemotherapy.

Key words

Immunosuppression Chemotherapy Acute lymphoblastic leukemia 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arya SK, Wong-Staar F, Gallo RC (1984) Dexamethasone-mediated inhibition of human T cell growth factor and γ-interferon messenger RNA. J Immunol 133: 273PubMedGoogle Scholar
  2. 2.
    Azuma E, Kaplan J (1988) Role of lymphokine activated killer cells as mediators of veto and natural suppression. J Immunol 142: 2601Google Scholar
  3. 3.
    Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A (1986) Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 232: 977PubMedGoogle Scholar
  4. 4.
    Borzy MS, Ridgway D (1989) Prolonged defects of interleukin-2 production, responsiveness, and receptor expression in patients with acute lymphoblastic leukemia. Blood 73: 1608PubMedGoogle Scholar
  5. 5.
    Dupont E, Huygen K, Schandene L, Vandercruys M, Palfliet K, Wybran J (1985) Influence of in vivo immunosuppressive drugs on production of lymphokines (1985) Transplantation 39: 143PubMedGoogle Scholar
  6. 6.
    Dupont E, Scandene L, Denys C, Wybran J (1986) Differential in vitro actions of cyclosporin, methylprednisolone, and 6-mercaptopurine: implications for drugs' influence on lymphocyte activation mechanisms. Clin Immunol Immunopathol 40: 422PubMedGoogle Scholar
  7. 7.
    Feldman S, Hughes WT, Kim HY (1973) Herpes zoster in children with cancer. Am J Dis Child 126: 178PubMedGoogle Scholar
  8. 8.
    Grills S, Crabtree GR, Smith KA (1979) Glucocorticoid-induced inhibition of T cell growth factor production: I. The effect on mitogen-induced lymphocyte proliferation. J Immunol 123: 1624PubMedGoogle Scholar
  9. 9.
    Guillou PJ, Giles GR, Ramsden CW (1986) Natural killer-cell activity, interferon-alpha 2 production, and interleukin-2 production on cyclosporin treated and conventionally immunosuppressed human allograft recipients. J Clin Immunol 6: 373PubMedGoogle Scholar
  10. 10.
    Hardy C, Feusner J, Harada S, Sanger W, Von Schmidt B, Yetz J, Saemundsen A, Lennette E, Linder J, Skeeley JK, Lubin B, Purtilo DT (1984) Fetal Epstein-Barr virus-induced lymphoproliferation complicating acute lymphoblastic leukemia. J Pediatr 105: 64PubMedGoogle Scholar
  11. 11.
    Hart PH, Vitti GF, Burgess DR, Whitty GA, Piccoli DS, Hamilton JA (1989) Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor α, interleukin 1, and prostaglandin E2. Proc Natl Acad Sci USA 86: 3803PubMedGoogle Scholar
  12. 12.
    Hayashi H, Kiyota T, Sakamoto H, Seto M (1985) An enzyme-linked immunosorbent assay for recombinant human tumor necrosis factor using monoclonal antibody. In: Seto M, Asahi C (eds) Recent advances in chemotherapy. Tokyo, Japan, p 820Google Scholar
  13. 13.
    Hughes WT, Feldman S, Cox F (1974) Infectious disease in children with cancer. Pediatr Clin North Am 21: 583PubMedGoogle Scholar
  14. 14.
    Ichimura O, Suzuki S, Saito M, Sugawara Y, Ishida N (1985) Augmentation of interleukin 1 and interleukin 2 production by OK-432. Int J Immunopharmacol 7: 263PubMedGoogle Scholar
  15. 15.
    Kaplan MP, Lysz K, Rosenberg SA, Rosenberg JC (1983) Suppression of interleukin-2 production by methylprednisone. Transplant Proc 15: 407Google Scholar
  16. 16.
    Kiyohara T, Taniguchi K, Kubota S, Koga S, Sakurai T, Saitoh Y (1988) Induction of lymphokine-activated killer-like cells by cancer chemotherapy. J Exp Med 168: 2355PubMedGoogle Scholar
  17. 17.
    Lee SW, Tsou A-P, Chan H, Thomas J, Petrie K, Eugui EM, Allison AC (1988) Glucocorticoids selectively inhibit the transcription of the interleukin 1β gene and decrease the stability of interleukin 1β mRNA. Proc Natl Acad Sci USA 85: 1204PubMedGoogle Scholar
  18. 18.
    Mantovani A, Luini W, Peri G, Vecchi A, Spreafico F (1978) Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice. J Natl Cancer Inst 61: 1255PubMedGoogle Scholar
  19. 19.
    Uchiyama T, Hori T, Tsudo M, Wano Y, Umadome H, Tamori S, Yodoi J, Maeda M, Sawami H, Uchino H (1985) Interleukin-2 receptor (Tac antigen) expressed in adult T-cell leukemia cells. J Clin Invest 76: 446PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • Yoshihiro Komada
    • 1
  • Shao-Li Zhang
    • 1
  • Yan-Wen Zhou
    • 1
  • Motoi Hanada
    • 1
  • Takeo Shibata
    • 1
  • Eiichi Azuma
    • 1
  • Minoru Sakurai
    • 1
  1. 1.Department of PediatricsMie University School of MedicineTsu, Mie-kenJapan

Personalised recommendations